180 related articles for article (PubMed ID: 15928251)
1. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and overactivation of Akt in thyroid carcinoma.
Ringel MD; Hayre N; Saito J; Saunier B; Schuppert F; Burch H; Bernet V; Burman KD; Kohn LD; Saji M
Cancer Res; 2001 Aug; 61(16):6105-11. PubMed ID: 11507060
[TBL] [Abstract][Full Text] [Related]
8. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
9. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
[TBL] [Abstract][Full Text] [Related]
10. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
[TBL] [Abstract][Full Text] [Related]
11. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084
[TBL] [Abstract][Full Text] [Related]
12. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
[TBL] [Abstract][Full Text] [Related]
14. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Hou P; Ji M; Xing M
Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
Jiang G; Huang Z; Zhang S; Wang L
Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
[TBL] [Abstract][Full Text] [Related]
16. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
[TBL] [Abstract][Full Text] [Related]
17. Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Murat CB; Braga PB; Fortes MA; Bronstein MD; Corrêa-Giannella ML; Giorgi RR
Braz J Med Biol Res; 2012 Sep; 45(9):851-5. PubMed ID: 22782554
[TBL] [Abstract][Full Text] [Related]
18. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
20. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
Lin Y; Jiang X; Shen Y; Li M; Ma H; Xing M; Lu Y
Endocr Relat Cancer; 2009 Mar; 16(1):301-10. PubMed ID: 18852163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]